30 November 2023 in Proceedings of the National Academy of Sciences
There has been considerable progress in the development of computational methods for designing protein–protein interactions, but engineering high-affinity binders without extensive screening and maturation remains challenging. Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist. With the goal of creating an anticancer agent that is inactive until reaching the tumor environment, we sought to create autoinhibited (or masked) forms of the PD-L1 antagonist that can be unmasked by tumor-enriched proteases. Twenty-three de novo designed AiDs, varying in length and topology, were fused to the antagonist with a protease-sensitive linker, and binding to PD-L1 was measured with and without protease treatment. Nine of the fusion proteins demonstrated conditional binding to PD-L1, and the top-performing AiDs were selected for further characterization as single-domain proteins. Without any experimental affinity maturation, four of the AiDs bind to the PD-L1 antagonist with equilibrium dissociation constants (K D s) below 150 nM, with the lowest K D equal to 0.9 nM. Our study demonstrates that DL-based protein modeling can be used to rapidly generate high-affinity protein binders.
15 August 2023 in Journal of the American Chemical Society
14 February 2026 in bioRxiv
Recent advances in machine learning (ML)-based protein design methods have enabled the rapid in silico generation of large libraries of miniprotein binders with minimal manual input. While computational design capacity has scaled rapidly, experimental validation methods have lagged, creating a bottleneck in binder discovery pipelines. Here, we apply mRNA display to screen an ML-designed miniprotein binder library and directly compare its performance with the more widely used yeast surface display platform using a single shared DNA library. We screened 2,009 designs targeting the platelet receptor TLT-1 and 3,159 designs targeting the immune receptor B7-H3 across both platforms. While both selection methods reliably identified functional binders, we found that mRNA display preferentially enriched binders with slower dissociation rates. In addition, mRNA display achieved higher library coverage than yeast display, likely rescuing functional designs that are penalized in a cell-based expression system. Biophysical characterization of selected binders from both platforms revealed strong binding affinities and high thermal stabilities. These results showcase the power of integrating ML-based computational design tools with rapid in vitro selection technologies, providing a scalable framework for therapeutic miniprotein discovery. IMPORTANCE: Miniprotein binders offer major advantages as next-generation therapeutics, including small size, high stability, and efficient production. In this work, we conduct a side-by-side comparison of mRNA and yeast display as platforms for high-throughput evaluation of de novo miniprotein binders. The binders generated here serve as starting points for therapeutics targeting TLT-1 or B7-H3, two clinically relevant molecules.